GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changchun BCHT Biotechnology Co (SHSE:688276) » Definitions » EBIT

Changchun BCHT Biotechnology Co (SHSE:688276) EBIT : ¥471 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Changchun BCHT Biotechnology Co EBIT?

Changchun BCHT Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥121 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥471 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Changchun BCHT Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 was 11.92%. Changchun BCHT Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 15.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Changchun BCHT Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 4.18%.


Changchun BCHT Biotechnology Co EBIT Historical Data

The historical data trend for Changchun BCHT Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changchun BCHT Biotechnology Co EBIT Chart

Changchun BCHT Biotechnology Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 272.14 490.70 261.90 197.69 564.46

Changchun BCHT Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 254.66 190.41 64.63 95.07 120.97

Competitive Comparison of Changchun BCHT Biotechnology Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Changchun BCHT Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changchun BCHT Biotechnology Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changchun BCHT Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Changchun BCHT Biotechnology Co's EV-to-EBIT falls into.



Changchun BCHT Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥471 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Changchun BCHT Biotechnology Co  (SHSE:688276) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Changchun BCHT Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=540.748 * ( 1 - 11.42% )/( (3936.058 + 4101.001)/ 2 )
=478.9945784/4018.5295
=11.92 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5134.948 - 842.024 - ( 356.866 - max(0, 964.24 - 2191.447+356.866))
=3936.058

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5313.957 - 935.066 - ( 277.89 - max(0, 1066.781 - 2174.56+277.89))
=4101.001

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Changchun BCHT Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=483.86/( ( (2195.367 + max(933.399, 0)) + (2346.966 + max(849.332, 0)) )/ 2 )
=483.86/( ( 3128.766 + 3196.298 )/ 2 )
=483.86/3162.532
=15.30 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1535.981 + 272.215 + 25.084) - (842.024 + 0 + 57.857)
=933.399

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1666.218 + 197.27 + 26.816) - (935.066 + 0 + 105.906)
=849.332

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Changchun BCHT Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=471.08/11280.237
=4.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Changchun BCHT Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Changchun BCHT Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Changchun BCHT Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1260, Huoju Road, High-tech Development Zone, Jilin Province, Changchun, CHN, 130012
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
Executives
Shi Nian Min Core technical personnel
Jiang Chun Lai Directors, senior managers, core technical personn
Zhu Chang Lin Core technical personnel
Wei Wei Senior management, core technical personnel
Yu Bing senior management
Liu Da Wei Senior management, core technical personnel
Meng Zhao Feng senior management
Zhang Zhe senior management
Kong Wei Directors, senior managers, core technical personn
Feng Da Qiang Supervisors

Changchun BCHT Biotechnology Co Headlines

No Headlines